Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04938505
Other study ID # 2018-A011828-47
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 4, 2019
Est. completion date May 4, 2025

Study information

Verified date June 2021
Source Centre Georges Francois Leclerc
Contact Sandrine DABAKUYO, PHD
Phone 0345348067
Email sdabakuyo@cgfl.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Nowadays, breast reconstruction is an integral care after mastectomy in breast cancer patient. With the personalized care, choice a breast reconstructive is an important step involving decisions and mutual accord between patients and their physicians in order to anticipate clinical and psychosocial results. Two main families of breast reconstruction techniques are often performed including advantages and complications impacting health related quality of life. Routine assessment of health related quality of life in patients underwent breast reconstruction could allow to identify factors of satisfaction o be taken into account in the choice of breast reconstruction technique in order to improve practices and quality of life of patients


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date May 4, 2025
Est. primary completion date May 4, 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Normal Breast Checkup ( Mammography, echography and breast magnetic resonance imaging)in the previous 6 months - French speaking and writing fluency - Agree to participate after receive all information Exclusion Criteria: - Patients with an inability to complete HRQOL questionnaires (cognitive disorders, language barrier) - Patient with a failed first breast reconstruction

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France Centre Georges Francois Leclerc Dijon

Sponsors (1)

Lead Sponsor Collaborator
Centre Georges Francois Leclerc

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Health related quality of life scores assessed by Breast Q questionnaire 12 months after breast reconstruction
Secondary Number of anxious and depress participants as assessed by Hospital Anxiety and Depression Scale (HADS) HADS has 14 items rated from 0 to 3 and covers 2 dimensions. Seven questions related to the anxiety dimension and seven other related to the depressive dimension, yielding 2 scores, A (Anxiety) and D (Depression). The maximum score for each dimension is 21. A score of 11 or higher indicates the probable presence of the disorder. 12 months after breast reconstruction
Secondary social support as assessed by Sarason's Social Support Questionnaire 6-item (SSQ6) Social support is measured across 2 dimensions: support availability, through the number of contacts that the patient can count on (0 to 9 people) and quality of support, through patient satisfaction with support received. Each item represents a situation in which the patient may need support. Patient is asked to cite the number of people that she could count on in that particular situation. Concerning the second item, the patient is asked to assess satisfaction with the support provided. The scores are generated according to Sarason's recommendations. A score is calculated for each dimension. Support availability score is calculated as the sum of the number of people available for the 6 items, this score ranges from 0 to 54, with 54 representing the highest availability. The social support satisfaction score is calculated by the sum of the satisfaction of the 6 items. This score ranges from 6 to 36, with 36 representing the highest level of satisfaction 12 months after breast reconstruction
Secondary level of the precariousness and the disparities of health at breast reconstruction patient by the questionnaire Evaluation of the Precariousness and the Disparities of Health for the Centers of Examination of Health (EPICES) EPICES is used to assess individual level of the precariousness. It includes 11 items and generate precariousness score from 0 to 100. Patient which a score EPICES >30 is considered as having a high level of precariousness 12 months after breast reconstruction
Secondary Health related quality of life scores assessed by Breast Q questionnaire 24 months after breast reconstruction
Secondary Health related quality of life scores assessed by Breast Q questionnaire 36 months after breast reconstruction
Secondary Health related quality of life scores assessed by Breast Q questionnaire 48 months after breast reconstruction
Secondary Health related quality of life scores assessed by Breast Q questionnaire 60 months after breast reconstruction
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A